
Galapagos NV (GLPGA) | Stock Overview & Key Data
Galapagos NV Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: €252.90 on February 17, 2020
Explore how other NL stocks compare to their 52-week ranges: View NL Market 52-Week Insights
Key Statistics
Financial Highlights
Profitability
Returns and Earnings
Growth
Peer Performance Comparison
Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
---|---|---|---|---|---|---|---|---|---|
Galapagos NV GLPGA | 1.90B Large-cap | -2.43% | 15.41% | 22.22% | 27.54% | 2.55% | 22.54% | -47.25% | -82.17% |
Pharming Group N.V PHARM | 720.78M Mid-cap | 8.25% | 20.69% | 38.16% | 26.51% | 9.38% | 44.44% | 1.96% | -4.59% |
Vivoryon VVY | 36.91M Small-cap | 0.70% | -0.69% | -17.82% | -26.29% | -31.90% | -31.60% | -81.92% | -73.00% |
Koninklijke Philips PHIA | 21.71B Large-cap | -1.47% | 10.97% | 6.85% | -14.40% | -7.06% | -14.11% | 16.26% | -48.95% |
ASML Holding N.V ASML | 243.41B Large-cap | -0.39% | -9.07% | 0.99% | -13.13% | -11.49% | -22.10% | 10.39% | 94.49% |
Shell plc SHELL | 181.59B Large-cap | -2.29% | 3.25% | 7.06% | -3.75% | -0.10% | -3.79% | 20.15% | 139.03% |
Ownership & Short Interest
Galapagos NV Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in Galapagos NV would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is GLPGA's 52-week high and low?
- In the last 52 weeks, Galapagos NV reached a high of €31.08 (on January 8, 2025) and a low of €20.00 (on April 7, 2025).
- What is the market cap and P/E ratio for GLPGA?
- Curious about Galapagos NV's size and valuation? Its market capitalization stands at 1.90B. When it comes to valuation, the P/E ratio (trailing twelve months) is 51.71, and the forward P/E (looking ahead) is -41.17.
- Does GLPGA pay dividends? If so, what's the yield?
- As for dividends, Galapagos NV isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Galapagos NV's main competitors or similar companies to consider before investing?
When looking at Galapagos NV, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Pharming Group N.V
PHARM720.78M Healthcare Biotechnology 44.44% 1.96% Vivoryon
VVY36.91M Healthcare Biotechnology -31.60% -81.92% Koninklijke Philips
PHIA21.71B Healthcare Medical Devices -14.11% 16.26% ASML Holding N.V
ASML243.41B Technology Semiconductor Equipment & Materials -22.10% 10.39% Shell plc
SHELL181.59B Energy Oil & Gas Integrated -3.79% 20.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Galapagos NV? (e.g., ROE, Debt/Equity)
- To get a sense of Galapagos NV's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -10.39%, the Debt to Equity ratio from the most recent quarter is 0.32, and its Gross Profit Margin stands at 92.79%.
- What is the recent revenue and earnings growth for GLPGA?
- Looking at Galapagos NV's growth, its revenue over the trailing twelve months (TTM) was €276M. Compared to the same quarter last year (YoY), quarterly revenue grew by -16.20%, and quarterly earnings saw a YoY growth of -16.16%.
- How much of GLPGA stock is held by insiders and institutions?
- Wondering who owns Galapagos NV stock? Company insiders (like executives and directors) hold about 25.36% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 31.85%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.